Evaluation of bioanalyzers for upstream commercial manufacturing by Apostolidis, Pani et al.
 Poster Number 103 
EVALUATION OF BIOANALYZERS FOR UPSTREAM COMMERCIAL MANUFACTURING 
 
Pani Apostolidis, Bristol-Myers Squibb Company, USA 
pani.apostolidis@bms.com 
Brandon Raghobir, Bristol-Myers Squibb Company, USA 
Ninad Patil, Bristol-Myers Squibb Company, USA 
Tim Diehl, Bristol-Myers Squibb Company, USA 
Eddie Crabbe, Bristol-Myers Squibb Company, USA 
Ron Bates, Bristol-Myers Squibb Company, USA 
 
 
The analyzer currently in use in one of our commercial manufacturing sites for measurement of pH, gases, 
metabolites and electrolytes during cell culture requires lengthy troubleshooting and excessive maintenance. 
This has led to loss of operator time and occasional disruption of manufacturing activities. The objective of this 
study was to replace the current membrane-based analyzer with a more reliable instrument. Two options were 
evaluated in an effort to reduce maintenance frequency and to minimize operator time spent troubleshooting. 
Option 1 was to employ a new generation, fully-automated membrane-based analyzer of the same type as the 
ones currently in place in the manufacturing suite. Option 2 was to employ a combination of a pH/gas analyzer 
and an absorption/photometric-based metabolite/electrolyte analyzer. Comparability between options 1 and 2 
and the analyzer currently in use at the manufacturing site was assessed in the laboratory using quality control 
standards and bioreactor samples from several commercial cell culture processes. Additionally, operational 
reliability and robustness of each option relative to the current analyzer as well as fit of the proposed analyzer 
options with other analyzers in place in commercial BMS facilities were taken into consideration. A summary of 
the advantages and pitfalls of each option to substitute the current analyzer in the context of a commercial 
manufacturing facility will be provided. 
 
